Pharmacology Course 2017: The Co-Morbid CVD Patient

Clinical management of chronic cardiovascular disease is a key component of the work of advanced practice nurses and RNs in the cardiology and primary care settings. PCNA’s annual pharmacology program meets the clinical practice and recertification needs of these clinicians.

Pharmacology
Member Cost: $45Non-member Cost: $115
Credits: 7.0 CE contact hours, 7.0 CE pharmacology hours

Course Overview

Register

Pharmacology for Chronic Cardiovascular Disease

Clinical management of chronic cardiovascular disease is a key component of the work of advanced practice nurses and RNs in the cardiology and primary care settings. PCNA’s annual pharmacology program meets the clinical practice and recertification needs of these clinicians.

This course curriculum includes a comprehensive approach to pharmacology in:

  1. Cardio-Metabolic Risk Reduction in Patients with Pre-Diabetes and DM2
  2. It’s a Balancing Act: Medication Management in Patients with CKD and CVD
  3. Pharmacological Management of the Cardiac Patient with Depression and/or Anxiety

This is an independent self-paced course with pre- and post-course evaluations.

Learning Objectives

Upon completion of this continuing education course, participants will be able to:

  • Understand the role of glucose lowering medications and their relationship with cardiovascular outcomes.
  • Describe the pharmacological treatments used for cardiovascular risk reduction in patients with diabetes and pre-diabetes.
  • Discuss safety and medication adherence when combining common antihypertensive, antilipemic, and blood sugar lowering therapies.
  • Review best practices in medication dosing, safety, and tolerance in patients with chronic kidney disease and cardiovascular disease.
  • Provide an overview of pharmacotherapies used to prevent the progression of renal dysfunction and reduce cardiovascular risk in patients with chronic kidney disease.
  • Describe how to select and titrate anti-depression and anti-anxiety therapies in patients with cardiovascular disease.
  • Review potential interactions between antidepressant/anti-anxiety therapies and common cardiovascular medications.

Faculty

  • Cindy Lamendola MSN, NP, FAHA, FPCNA
  • Carol Headley DNSc., ACNP, RN, CNN
  • Wei Jiang, MD